| Pair Name | Shikonin, Osimertinib | ||
| Phytochemical Name | Shikonin (PubChem CID: 479503 ) | ||
| Anticancer drug Name | Osimertinib (PubChem CID: 71496458 ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Pair Name | Shikonin, Osimertinib | |||
| Disease Info | [ICD-11: 2C25] | Lung cancer | Investigative | |
| Biological Phenomena | InductionROS generation | |||
| Gene Regulation | Up-regulation | Expression | ATF4 | hsa468 |
| Up-regulation | Phosphorylation | EIF2S1 | hsa1965 | |
| In Vitro Model | A-549 | Lung adenocarcinoma | Homo sapiens (Human) | CVCL_0023 |
| NCI-H1299 | Lung large cell carcinoma | Homo sapiens (Human) | CVCL_0060 | |
| NCI-H460 | Lung large cell carcinoma | Homo sapiens (Human) | CVCL_0459 | |
| Result | Shikonin increased the anticancer activity of AZD9291 in primary wtEGFR NSCLC cells through ROS-mediated ER stress | |||
| No. | Title | Href |
|---|---|---|
| 1 | A natural anthraquinone derivative shikonin synergizes with AZD9291 against wtEGFR NSCLC cells through reactive oxygen species-mediated endoplasmic reticulum stress. Phytomedicine. 2020 Mar;68:153189. doi: 10.1016/j.phymed.2020.153189. | Click |
